Cargando…

Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma

Nivolumab-induced multiple organ immune-related adverse events (irAEs) have been described in some case reports. The symptoms of endocrinological irAEs are especially nonspecific. A 63-year-old man with a postoperative recurrence of pulmonary adenocarcinoma who was treated with nivolumab presented f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishima, Yuka, Fukaishi, Takahiro, Inase, Naohiko, Isogai, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443556/
https://www.ncbi.nlm.nih.gov/pubmed/30449786
http://dx.doi.org/10.2169/internalmedicine.1268-18
_version_ 1783407852901105664
author Mishima, Yuka
Fukaishi, Takahiro
Inase, Naohiko
Isogai, Susumu
author_facet Mishima, Yuka
Fukaishi, Takahiro
Inase, Naohiko
Isogai, Susumu
author_sort Mishima, Yuka
collection PubMed
description Nivolumab-induced multiple organ immune-related adverse events (irAEs) have been described in some case reports. The symptoms of endocrinological irAEs are especially nonspecific. A 63-year-old man with a postoperative recurrence of pulmonary adenocarcinoma who was treated with nivolumab presented fever, anorexia and fatigue after the 7th cycle. He underwent a rapid adrenocorticotrophic hormone test, four-hormone tolerance test and thyroid gland scintigraphy. The results were consistent with destructive thyroiditis, hypophysitis and secondary adrenal insufficiency. Nivolumab was restarted following glucocorticoid and thyroid hormone replacement treatment. When a patient presents nonspecific symptoms, the possibility of endocrinological irAEs should be considered as it may enable their early detection.
format Online
Article
Text
id pubmed-6443556
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-64435562019-04-02 Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma Mishima, Yuka Fukaishi, Takahiro Inase, Naohiko Isogai, Susumu Intern Med Case Report Nivolumab-induced multiple organ immune-related adverse events (irAEs) have been described in some case reports. The symptoms of endocrinological irAEs are especially nonspecific. A 63-year-old man with a postoperative recurrence of pulmonary adenocarcinoma who was treated with nivolumab presented fever, anorexia and fatigue after the 7th cycle. He underwent a rapid adrenocorticotrophic hormone test, four-hormone tolerance test and thyroid gland scintigraphy. The results were consistent with destructive thyroiditis, hypophysitis and secondary adrenal insufficiency. Nivolumab was restarted following glucocorticoid and thyroid hormone replacement treatment. When a patient presents nonspecific symptoms, the possibility of endocrinological irAEs should be considered as it may enable their early detection. The Japanese Society of Internal Medicine 2018-11-19 2019-03-01 /pmc/articles/PMC6443556/ /pubmed/30449786 http://dx.doi.org/10.2169/internalmedicine.1268-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Mishima, Yuka
Fukaishi, Takahiro
Inase, Naohiko
Isogai, Susumu
Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title_full Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title_fullStr Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title_full_unstemmed Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title_short Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
title_sort nivolumab-induced hypophysitis, secondary adrenal insufficiency and destructive thyroiditis in a patient with lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443556/
https://www.ncbi.nlm.nih.gov/pubmed/30449786
http://dx.doi.org/10.2169/internalmedicine.1268-18
work_keys_str_mv AT mishimayuka nivolumabinducedhypophysitissecondaryadrenalinsufficiencyanddestructivethyroiditisinapatientwithlungadenocarcinoma
AT fukaishitakahiro nivolumabinducedhypophysitissecondaryadrenalinsufficiencyanddestructivethyroiditisinapatientwithlungadenocarcinoma
AT inasenaohiko nivolumabinducedhypophysitissecondaryadrenalinsufficiencyanddestructivethyroiditisinapatientwithlungadenocarcinoma
AT isogaisusumu nivolumabinducedhypophysitissecondaryadrenalinsufficiencyanddestructivethyroiditisinapatientwithlungadenocarcinoma